MCID: LPP002
MIFTS: 46

Lipoprotein Glomerulopathy malady

Categories: Genetic diseases, Nephrological diseases, Metabolic diseases, Endocrine diseases, Rare diseases

Aliases & Classifications for Lipoprotein Glomerulopathy

About this section
Sources:
12diseasecard, 24GeneTests, 26GTR, 30ICD10 via Orphanet, 36MedGen, 51OMIM, 53Orphanet, 67UMLS, 69UniProtKB/Swiss-Prot
See all MalaCards sources

Aliases & Descriptions for Lipoprotein Glomerulopathy:

Name: Lipoprotein Glomerulopathy 51 24 53 69 26 12 67
 
Lpg 24 53 69

Characteristics:

Orphanet epidemiological data:

53
lipoprotein glomerulopathy:
Inheritance: Autosomal dominant; Age of onset: All ages

Classifications:



External Ids:

OMIM51 611771
Orphanet53 ORPHA329481
ICD10 via Orphanet30 N07.8
MedGen36 C2673196

Summaries for Lipoprotein Glomerulopathy

About this section
OMIM:51 Lipoprotein glomerulopathy is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and... (611771) more...

MalaCards based summary: Lipoprotein Glomerulopathy, also known as lpg, is related to dysmorphism-pectus carinatum-joint laxity syndrome and casr-related disorders, and has symptoms including renal insufficiency, proteinuria and mesangial abnormality. An important gene associated with Lipoprotein Glomerulopathy is APOE (Apolipoprotein E), and among its related pathways are amb2 Integrin signaling and A-beta Pathways: Uptake and Degradation. Affiliated tissues include kidney and endothelial, and related mouse phenotypes are liver/biliary system and pigmentation.

UniProtKB/Swiss-Prot:69 Lipoprotein glomerulopathy: Uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries.

Related Diseases for Lipoprotein Glomerulopathy

About this section

Diseases related to Lipoprotein Glomerulopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 51)
idRelated DiseaseScoreTop Affiliating Genes
1dysmorphism-pectus carinatum-joint laxity syndrome10.3APOB, APOE
2casr-related disorders10.3APOB, APOE
3respiratory syncytial virus infectious disease10.3APOE, LPA
4islet cell tumor10.3APOB, APOE
5peripheral degeneration of cornea10.2APOB, APOE
6pontocerebellar hypoplasia10.2APOB, APOE
7fetal methyl mercury syndrome10.1APOB, LCAT
8bone angioendothelial sarcoma10.1APOB, LPA
9blue toe syndrome10.1APOB, LCAT
10night blindness, congenital stationary , 1d, autosomal recessive10.1APOE, CLU
11tyrosinemia, type ii10.0APOA2, LCAT
12dermal unilateral segmental cavernous angioma10.0APOB, APOE, LPA
13angina pectoris10.0APOB, LPA
14atherosclerosis9.9
15glossopharyngeal nerve neoplasm9.9APOB, APOE, LPA
16iron metabolism disease9.9APOB, APOE, LPA
17littre gland carcinoma9.9APOB, APOE, LPA
18stroke, ischemic9.9APOB, APOE, LPA
19wolfram syndrome 29.9APOB, APOE, LCAT
20afibrinogenemia, congenital9.9APOA2, LPA
21dyserythropoietic anemia, congenital, type ii9.8LCAT, LPA
22hemochromatosis, type 59.7APOE, LDLR
23glomerulonephritis9.7
24malignant hypertension9.7
25psoriasis9.7
26fibrillary glomerulonephritis9.7
27endotheliitis9.7
28cardiomyopathy, dilated, 1u9.7APOE, CLU
29hypercholesterolemia, due to ligand-defective apo b9.6APOB, APOE, LDLR
30arthritis9.6APOE, LDLR, LPA
31chondrocalcinosis with early-onset osteoarthritis9.5APOB, APOE, LCAT, LPA
32rubinstein taybi like syndrome9.3APOB, APOE, LDLR, LPA
33keratoacanthoma9.3APOB, APOE, LDLR, LPA
34adrenal rest tumor9.3APOB, APOE, LDLR, LPA
35autoimmune hepatitis9.2APOB, APOE, LDLR, LPA
36degos 'en cocarde' erythrokeratoderma9.2APOB, APOE, LCAT, LDLR
37hypobetalipoproteinemia9.2APOB, APOE, LCAT, LDLR
38polyneuropathy9.0APOA2, APOB, APOE, LCAT, LPA
39obesity, hyperphagia, and developmental delay9.0APOA2, APOB, APOE, LCAT, LPA
40hyperlipidemia, familial combined9.0APOA2, APOB, LCAT, LDLR
41cataract 5, multiple types9.0APOA2, APOB, LCAT, LDLR
42inflamed seborrheic keratosis8.8APOA2, APOB, APOE, LDLR, LPA
43immunodeficiency 198.7APOA2, APOB, APOE, LDLR, LPA
44myocardial infarction8.7APOA2, APOB, APOE, LDLR, LPA
45bladder diverticulum8.3APOA2, APOB, APOE, LCAT, LDLR, LPA
46von willebrand disease, platelet-type8.3APOA2, APOB, APOE, LCAT, LDLR, LPA
47apolipoprotein c-iii deficiency8.3APOA2, APOB, APOE, LCAT, LDLR, LPA
48narcolepsy 68.3APOA2, APOB, APOE, LCAT, LDLR, LPA
49peripheral artery disease8.3APOA2, APOB, APOE, LCAT, LDLR, LPA
50coronary artery disease8.3APOA2, APOB, APOE, LCAT, LDLR, LPA

Graphical network of the top 20 diseases related to Lipoprotein Glomerulopathy:



Diseases related to lipoprotein glomerulopathy

Symptoms for Lipoprotein Glomerulopathy

About this section


Clinical features from OMIM:

611771

Human phenotypes related to Lipoprotein Glomerulopathy:

 63
id Description HPO Frequency HPO Source Accession
1 renal insufficiency63 HP:0000083
2 proteinuria63 HP:0000093
3 mesangial abnormality63 HP:0001966
4 glomerulopathy63 HP:0100820

Drugs & Therapeutics for Lipoprotein Glomerulopathy

About this section

Drugs for Lipoprotein Glomerulopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Irbesartanapproved, investigational101138402-11-63749
Synonyms:
138402-11-6
2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one
2-Butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one
2-butyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[
2-butyl-3-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[
2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one
8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
AC-537
AC1L1GMK
Aprovel
Avalide
Avapro
Avapro (TN)
BIDD:GT0347
BMS 186295
BMS Brand of Irbesartan
BMS-186295
BMS-186295, SR-47436, Aprovel, Karvea, Irbesartan
BRD-K60038276-001-02-5
BSPBio_002687
Bio-0053
Bristol Myers Brand of Irbesartan
C07469
C081309
C25H28N6O
CHEBI:5959
CHEMBL1513
CID3749
CPD000466306
D00523
DB01029
HMS1922J05
HMS2051L08
HMS2093E16
 
I06-0690
Irbesarran
Irbesartan
Irbesartan (JAN/USAN/INN)
Irbesartan [USAN:INN]
Irbesartan [Usan:Inn]
Irbetan
Jsp002315
KBio2_002231
KBio2_004799
KBio2_007367
KBio3_001907
KBioGR_001603
KBioSS_002231
Karvea
L000319
LS-60064
Lrbesartan
MLS000759408
MLS001424099
MolPort-003-666-550
NCGC00095122-01
NCGC00095122-02
NCGC00095122-03
S1507_Selleck
SAM001246548
SMR000466306
SPBio_001889
SPECTRUM1504259
SR 47436
SR-47436
STK645362
Sanofi Winthrop Brand of Irbesartan
Spectrum2_001675
Spectrum3_000994
Spectrum4_001122
Spectrum5_001288
Spectrum_001751
TL8000875
UNII-J0E2756Z7N
irbesartan
2
Sevelamerapproved7452757-95-6, 152751-57-03085017
Synonyms:
Sevelamer
 
Sevelamero
Sevelamerum
Sévélamer
3
Uric Acidexperimental, investigational13369-93-21175
Synonyms:
1H-Purine-2,6,8-triol
2,6,8-Trihydroxypurine
2,6,8-Trioxopurine
2,6,8-Trioxypurine
 
7,9-dihydro-1H-purine-2,6,8(3H)-trione
Lithate
Lithic acid
Purine-2,6,8(1H,3H,9H)-trione
Urate
Uric acid
4Chelating Agents1365
5Antihypertensive Agents4095
6Angiotensin II Type 1 Receptor Blockers1078
7Angiotensin Receptor Antagonists1173
8Angiotensinogen1161
9
Angiotensin II116268521-88-0, 11128-99-7172198, 65143
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II

Interventional clinical trials:

idNameStatusNCT IDPhase
1Therapeutic Effect of Immunoadsorption for Patients With Lipoprotein GlomerulopathyCompletedNCT00302510
2A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related GlomerulopathyRecruitingNCT02644486

Search NIH Clinical Center for Lipoprotein Glomerulopathy

Genetic Tests for Lipoprotein Glomerulopathy

About this section

Genetic tests related to Lipoprotein Glomerulopathy:

id Genetic test Affiliating Genes
1 Lipoprotein Glomerulopathy26 24 APOE

Anatomical Context for Lipoprotein Glomerulopathy

About this section

MalaCards organs/tissues related to Lipoprotein Glomerulopathy:

35
Kidney, Endothelial

Animal Models for Lipoprotein Glomerulopathy or affiliated genes

About this section

MGI Mouse Phenotypes related to Lipoprotein Glomerulopathy:

40
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.0APOB, APOE, LCAT, LDLR
2MP:00011868.9APOB, APOE, LDLR
3MP:00053858.6APOB, APOE, CLU, LCAT, LDLR
4MP:00053767.9APOA2, APOB, APOE, CLU, LCAT, LDLR

Publications for Lipoprotein Glomerulopathy

About this section

Articles related to Lipoprotein Glomerulopathy:

(show top 50)    (show all 84)
idTitleAuthorsYear
1
SPONTANEOUS LIPOPROTEIN GLOMERULOPATHY-LIKE NEPHROPATHY IN A SQUIRREL (SCIURUS VULGARIS). (27468047)
2016
2
Lipoprotein glomerulopathy: a case report of a rare disease in a Brazilian child. (24676620)
2014
3
Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice. (25183802)
2014
4
Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis. (24487366)
2014
5
Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia. (24570178)
2014
6
Long-term outcome of kidney transplantation in a patient with coexisting lipoprotein glomerulopathy and fibrillary glomerulonephritis. (25852917)
2014
7
Hereditary features, treatment, and prognosis of the lipoprotein glomerulopathy in patients with the APOE Kyoto mutation. (24025644)
2013
8
A case of lipoprotein glomerulopathy with thrombotic microangiopathy due to malignant hypertension. (23448537)
2013
9
A possible structural basis behind the pathogenic role of apolipoprotein E hereditary mutations associated with lipoprotein glomerulopathy. (24149834)
2013
10
Topics in lipoprotein glomerulopathy: an overview. (24149835)
2013
11
Lipoprotein glomerulopathy in China. (24165683)
2013
12
A founder haplotype of APOE-Sendai mutation associated with lipoprotein glomerulopathy. (23407349)
2013
13
A rare cause of childhood-onset nephrotic syndrome: lipoprotein glomerulopathy. (22874113)
2012
14
Scavenger receptor expressions in the kidneys of mice with lipoprotein glomerulopathy. (22072188)
2012
15
Identification of a mutation in exon 4 of apolipoprotein E gene in a family affected with lipoprotein glomerulopathy]. (22487820)
2012
16
A novel apolipoprotein E mutation, ApoE Osaka (Arg158 Pro), in a dyslipidemic patient with lipoprotein glomerulopathy. (21325775)
2011
17
A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. (20121619)
2010
18
Common apolipoprotein E gene mutations contribute to lipoprotein glomerulopathy in China. (20090368)
2010
19
A rare cause of nephrotic syndrome: lipoprotein glomerulopathy. (19197098)
2009
20
Improvement of nephrotic syndrome by intensive lipid-lowering therapy in a patient with lipoprotein glomerulopathy. (19603250)
2009
21
Lipoprotein glomerulopathy treated with LDL-apheresis (Heparin-induced Extracorporeal Lipoprotein Precipitation system): a case report. (20062740)
2009
22
Clinicopathological and genetic characteristics in Chinese patients with lipoprotein glomerulopathy. (18264944)
2008
23
A novel apolipoprotein E mutation, ApoE Tsukuba (Arg 114 Cys), in lipoprotein glomerulopathy. (17967799)
2008
24
Renal failure with intracapillary thrombi. Lipoprotein glomerulopathy. (18414445)
2008
25
A complete genomic analysis of the apolipoprotein E gene in Chinese patients with lipoprotein glomerulopathy. (17918142)
2007
26
APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy. (18077821)
2007
27
Lipoprotein glomerulopathy-like disease in a patient with type III hyperlipoproteinemia due to apolipoprotein E2 (Arg158 Cys)/3 heterozygosity. (17593519)
2007
28
Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. (16490634)
2006
29
Clinical and pathological analyses of lipoprotein glomerulopathy]. (15181857)
2004
30
Disappearance of intraglomerular lipoprotein thrombi and marked improvement of nephrotic syndrome by bezafibrate treatment in a patient with lipoprotein glomerulopathy. (12921981)
2003
31
Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy. (12500244)
2003
32
A patient with apolipoprotein E2 variant (Q187E) without lipoprotein glomerulopathy. (11877595)
2002
33
Interaction of endothelial cells and triglyceride-rich lipoproteins with apolipoprotein E (Arg-->Cys) from a patient with lipoprotein glomerulopathy. (11833049)
2002
34
Diminished LDL receptor and high heparin binding of apolipoprotein E2 Sendai associated with lipoprotein glomerulopathy. (11181800)
2001
35
A newborn infant with lipoprotein glomerulopathy associated with congenital nephrotic syndrome. (11208006)
2001
36
A new variant of apolipoprotein E (apo E Maebashi) in lipoprotein glomerulopathy. (10684367)
2000
37
A novel 18-amino acid deletion in apolipoprotein E associated with lipoprotein glomerulopathy. (10504484)
1999
38
Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Implications for renal transplantation. (10052520)
1999
39
Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. (10405216)
1999
40
Association of apolipoprotein E polymorphism with lipoprotein glomerulopathy. Report of 2 cases with a new genotype and comparison of the relative frequencies of apolipoprotein E isoforms in lipoprotein glomerulopathy and in the general population. (9546684)
1998
41
Lipoprotein glomerulopathy and its pathogenesis. (9257045)
1997
42
Lipoprotein glomerulopathy: a pediatric case report. (9090668)
1997
43
Lipoprotein glomerulopathy: a new apolipoprotein-E-related disease that recurs after renal transplantation. (9270770)
1997
44
Lipoprotein glomerulopathy: a new role for apolipoprotein E? (9176856)
1997
45
Lipoprotein glomerulopathy: first case in a white European. (7624001)
1995
46
Lipoprotein glomerulopathy with a new apolipoprotein E phenotype. (7771495)
1995
47
A case of lipoprotein glomerulopathy successfully treated with probucol. (8052351)
1994
48
A case of lipoprotein glomerulopathy. Light and electron microscopic observations of the glomerulus. (2392939)
1990
49
Lipoprotein glomerulopathy: glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. (2644825)
1989
50
Similarities between glomerular sclerosis and atherosclerosis in human renal biopsy specimens: a role for lipoprotein glomerulopathy. (2486545)
1989

Variations for Lipoprotein Glomerulopathy

About this section

UniProtKB/Swiss-Prot genetic disease variations for Lipoprotein Glomerulopathy:

69
id Symbol AA change Variation ID SNP ID
1APOEp.Arg43CysVAR_042734rs121918399
2APOEp.Arg163ProVAR_042735rs121918397

Clinvar genetic disease variations for Lipoprotein Glomerulopathy:

5
id Gene Variation Type Significance SNP ID Assembly Location
1APOENM_000041.3(APOE): c.488G> C (p.Arg163Pro)SNVPathogenicrs121918397GRCh37Chr 19, 45412041: 45412041
2APOENM_000041.3(APOE): c.127C> T (p.Arg43Cys)SNVPathogenicrs121918399GRCh37Chr 19, 45411100: 45411100

Expression for genes affiliated with Lipoprotein Glomerulopathy

About this section
Search GEO for disease gene expression data for Lipoprotein Glomerulopathy.

Pathways for genes affiliated with Lipoprotein Glomerulopathy

About this section

Pathways related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.6APOB, LPA
29.3APOE, LDLR
3
Show member pathways
8.2APOA2, APOB, APOE, LDLR
4
Show member pathways
8.2APOA2, APOB, APOE, LDLR
5
Show member pathways
7.7APOA2, APOB, APOE, LCAT, LDLR
6
Show member pathways
7.3APOA2, APOB, APOE, LCAT, LDLR, LPA
7
Show member pathways
7.3APOA2, APOB, APOE, LCAT, LDLR, LPA

GO Terms for genes affiliated with Lipoprotein Glomerulopathy

About this section

Cellular components related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

(show all 13)
idNameGO IDScoreTop Affiliating Genes
1intermediate-density lipoprotein particleGO:003436310.4APOB, APOE
2endocytic vesicle lumenGO:007168210.4APOB, APOE
3spherical high-density lipoprotein particleGO:003436610.0APOA2, CLU
4clathrin-coated endocytic vesicle membraneGO:00306699.9APOB, LDLR
5chylomicronGO:00426279.8APOA2, APOB, APOE
6very-low-density lipoprotein particleGO:00343619.8APOA2, APOB, APOE
7high-density lipoprotein particleGO:00343649.6APOA2, APOE, LCAT
8low-density lipoprotein particleGO:00343629.6APOB, APOE, LDLR
9blood microparticleGO:00725629.0APOA2, APOE, CLU
10early endosomeGO:00057698.5APOA2, APOB, APOE, LDLR
11Golgi apparatusGO:00057948.4APOB, APOE, CLU, LDLR
12extracellular spaceGO:00056157.7APOA2, APOB, APOE, CLU, LCAT
13extracellular regionGO:00055767.5APOA2, APOB, APOE, CLU, LCAT, LPA

Biological processes related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

(show all 27)
idNameGO IDScoreTop Affiliating Genes
1artery morphogenesisGO:004884410.2APOB, APOE
2positive regulation of cholesterol esterificationGO:001087310.1APOA2, APOE
3phospholipid effluxGO:003370010.1APOA2, APOE
4very-low-density lipoprotein particle remodelingGO:003437210.1APOE, LCAT
5high-density lipoprotein particle assemblyGO:003438010.1APOA2, APOE
6high-density lipoprotein particle clearanceGO:003438410.1APOA2, APOE
7negative regulation of beta-amyloid formationGO:190243010.1APOE, CLU
8protein importGO:001703810.1APOE, CLU
9regulation of beta-amyloid clearanceGO:190022110.1APOE, CLU
10triglyceride catabolic processGO:001943310.0APOB, APOE
11lipid transportGO:00068699.9APOA2, LPA
12phosphatidylcholine biosynthetic processGO:00066569.9APOA2, LCAT
13triglyceride metabolic processGO:00066419.8APOA2, APOE
14cholesterol effluxGO:00333449.7APOA2, APOB, APOE
15low-density lipoprotein particle remodelingGO:00343749.6APOA2, APOB, APOE
16low-density lipoprotein particle clearanceGO:00343839.6APOB, LDLR
17high-density lipoprotein particle remodelingGO:00343759.5APOA2, APOE, LCAT
18lipoprotein catabolic processGO:00421599.4APOB, APOE, LDLR
19lipoprotein biosynthetic processGO:00421589.2APOA2, APOB, APOE, LCAT
20retinoid metabolic processGO:00015239.1APOA2, APOB, APOE
21reverse cholesterol transportGO:00436918.9APOA2, APOE, CLU, LCAT
22receptor-mediated endocytosisGO:00068988.9APOB, APOE, LDLR
23cholesterol transportGO:00303018.6APOA2, APOB, LCAT, LDLR
24lipid metabolic processGO:00066298.0APOB, APOE, CLU, LDLR, LPA
25cholesterol homeostasisGO:00426328.0APOA2, APOB, APOE, LCAT, LDLR
26cholesterol metabolic processGO:00082037.9APOA2, APOB, APOE, LCAT, LDLR
27lipoprotein metabolic processGO:00421577.7APOA2, APOB, APOE, LCAT, LDLR, LPA

Molecular functions related to Lipoprotein Glomerulopathy according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1phosphatidylcholine-sterol O-acyltransferase activator activityGO:006022810.1APOA2, APOE
2cholesterol bindingGO:00154859.9APOA2, APOE
3lipid transporter activityGO:00053199.9APOA2, APOE
4low-density lipoprotein particle receptor bindingGO:00507509.7APOB, APOE
5cholesterol transporter activityGO:00171279.5APOA2, APOB, APOE
6heparin bindingGO:00082019.5APOB, APOE, LPA
7phospholipid bindingGO:00055439.1APOA2, APOB, APOE
8lipid bindingGO:00082898.8APOA2, APOB, APOE

Sources for Lipoprotein Glomerulopathy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet